Epstein–Barr virus nuclear antigen 3C (EBNA-3C) is a small subset of latent antigens critical for the transformation of human primary B lymphocytes into continuously proliferating lymphoblastoid cell lines (LCLs)
in vitro through manipulation of a number of major cellular pathways. Moreover, EBNA-3C can stabilize c-Myc and enhance c-Myc-dependent transcription. EBNA-3C residues 130 to 190 recruit and modulate the activity of retinoblastoma (Rb) and p27, both major regulators of the mammalian cell cycle. The inclusion of c-Myc in the group of cellular targets modulated by this domain further accentuates the importance of these critical residues of EBNA-3C in bypassing the cell cycle checkpoints [
62]. An EBV recombinant deleted for residues 130–159 in EBNA-3C can deregulate p53/Mdm2 and cyclin D1/CDK6 which results in apoptosis and reduce cell proliferation [
63]. The inhibitor of growth (ING), a tumor suppressor, can be divided into three categories: one is ING1 and ING2, and ING4 and ING5 are classified as type II, while ING3 is different from other members [
64,
65]. Saha et al. found that EBNA-3C nullified the positive regulation of both ING4 and ING5 in the tumor suppressive activity of p53 [
66]. The p73 protein has structural and functional homology with the tumor suppressor p53. Sahu et al. discovered that the repressive effects of EBNA-3C on p73 function increased the efficiency of EBV-mediated lymphomagenesis. Interestingly, there is a colocalization between EBNA-3C and nuclear p73 [
67]. The role of the pRb-E2F pathway in the regulation of cell cycle progression, particularly the G
1/S transition, is well established. E2F1 plays a dual role in controlling cell growth and apoptosis. For example, elevated expression of E2F1 promotes cell cycle progression by driving quiescent cells into S phase [
68]. However, E2F1 expression can also induce apoptosis in the absence of proliferative signals [
69]. Saha et al. discovered that EBNA-3C efficiently blocked E2F1-mediated apoptosis, as well as its anti-proliferative effects in a p53-independent manner, in response to DNA damage [
70]. E2F6 is one of the E2F family members with a unique property of transcriptional repression. E2F6 recruited together with EBNA3C binds E2F1 promoter and inhibits its activity, which contributes to B cell proliferation by reducing the expression of E2F1 [
71]. EBNA-3C and EBNA-3A jointed repression of CDKN2A p16
INK4A and p14
ARF was essential for LCL growth, was reported by Maruo et al. [
72]. These suggest that EBNA-3C can facilitate G
1 to S transition. Accordingly, EBNA-3C inhibits p73, p14
ARF and p16
INK4A to promote G
1/S transition. At the same time, the combination of EBNA-3C and E2F6 can effectively block E2F1-mediated apoptosis and promote cell proliferation.
Additionally, Rovedo et al. [
73] showed that LMP-2B negatively regulates the activity of LMP-2A. As described by White et al. [
74], EBNA-3B is dispensable for B cell transformation in vitro. EBNA-3B is a virally encoded tumor suppressor gene that inhibits EBV-transformed B cell proliferation to ensure long-term survival of the persistently infected host.